Advanced Forum on R&D Strategies for Improved New Drugs
Against the backdrop of industry development slowdown, the motivation and funding for innovative drug research and development are somewhat insufficient. Affected by drug centralized procurement policies, generic drug profits are becoming increasingly low, making it more difficult to initiate research projects. Improved new drugs are receiving increasing attention from enterprises due to their relatively shorter research and development cycles, lower costs, and higher returns.
In response to the above issues,2024year1month13day after tomorrow14day2024The Annual High-End Forum on Innovative New Drug R&D Strategies was successfully held in Yueyang, Hunan Province. The forum was organized by the People's Government of Yueyang County and the Hunan Pharmaceutical Association.505b2 platformCo-organized by the School of Pharmacy, Xiangya Medicine College of Central South University, Yueyang High-tech Industrial Park, Hunan Huize Biomedical Technology Co., Ltd., Beijing Zhaoyan New Drug Research Center Co., Ltd., and Nuozhen Technology(shanghai)Jointly organized by a limited liability company, with the National Federation of Industry and Commerce Pharmaceutical Business Chamber of Commerce serving as the guiding unit.
This forum invited experts who have long been engaged in new drug review to share project initiation strategies; experts from Peking University, China Pharmaceutical University, Shenyang Pharmaceutical University, Central South University, Jinan University, and other institutions shared their expert insights; preclinical research and clinical trial experts shared R&D application strategies; industry experts shared successful case experiences; pharmacoeconomic evaluation experts and industry experts shared commercialization strategies from the perspectives of policies and successful cases. In addition, the conference specially invited Academician Zhang Lihe as the chairperson of the conference and Academician Zhang Qiang for a keynote speech.
This forum aims to build an open, equal, and close-knit communication platform between enterprises and experts, as well as a session for exchanging the latest research and development achievements and progress, to seek cooperation opportunities and discuss 'pharmaceutical' strategies for improvement.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the forum and delivered a speech on 'Analysis of the Investment and Financing Assets Market for Improved New Drugs'.
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua briefly analyzed The current industry status and future development trends of improved new drugs. He pointed out that improved new drugs are based on existing drugs and undergo modifications, possessing significant clinical and industrial advantages. The research and development of improved new drugs requires low investment and risk, with high commercial returns. In recent years, the number of clinical applications for improved new drugs has been increasing year by year, as of2023year12Month, there are already in China40An improved new drug has been approved for marketing,276An improved new drug is in the clinical trial and marketing application stages.
Mao Hua said that although China's innovative new drug development started relatively late, it has now entered a stage of rapid growth. In recent years, there has been an increase in transactions in the global field of innovative new drugs, with an increase in the number of collaborations, licensing, and transactional agreements among Chinese innovative new drug companies. In the future, with the growth and upgrading of therapeutic needs, the improvement of innovative formulation technologies, and favorable policy drivers, the market for innovative new drugs will develop rapidly.
The administration routes of innovative formulations are diverse, capable of meeting the clinical needs of different patients. Currently, the formulation innovation of innovative formulations is developing in a diversified manner. According to Frost & Sullivan research, the innovative formulation products under development cover multiple indication types, with main research areas including nervous system drugs, anti-tumor drugs, endocrine and metabolic drugs, and cardiovascular system drugs. Mao Hua pointed out that innovative formulations are an important factor driving the growth of the market for improved new drugs. Compared to traditional formulations, innovative formulations can improve medication compliance, enhance drug therapies, fill medication gaps, and reduce toxic and side effects. Therefore, they account for the largest proportion in the approved and under-development landscape. It is expected that in2030In 2024, innovative formulations will account for nearly half of improved new drugs.
"Innovative formulation products are continuously upgrading and iterating towards longer drug efficacy durations and lower dosing frequencies, enhancing the clinical advantages of products while extending their lifecycle. In addition, there will be more products with different new technology types for the same active ingredient, which may change the market landscape of innovative formulations in China. In the future, under the premise of policy subsidies and equivalence, domestic innovative formulations "There is huge room for import substitution," Mao Hua said.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating a wealth of project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting, among others. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received widespread attention from investors.
